For the millions living in the shadow of long COVID, the fog of exhaustion and lost motivation has long resisted explanation — and with it, the credibility that suffering often requires to be taken seriously. Now, PET imaging has revealed measurable damage to the brain's dopamine system in long COVID patients, with specific injuries mapping precisely onto specific symptoms: lost motivation, slowed movement, impaired memory. The discovery not only illuminates a biological mechanism behind one of the pandemic's most enduring legacies, but points toward existing medications that may, at last, off
PET Imaging Links Dopamine Neuron Injury to Long COVID Symptoms
Approximately 9 million US adults and 5% of global population experience debilitating long COVID symptoms including fatigue, cognitive impairment, and reduced mobility.
The dopamine system damage is visible. It is measurable. It is real.
Mark
Why does dopamine matter so much here? It's one neurotransmitter among many in the brain.
Mimi
Dopamine isn't just about pleasure or reward—it's the fuel for motivation, movement, and working memory. When it's damaged, you don't just feel sad; you lose the drive to do things, your body moves slower, and your mind gets foggy. That's exactly what long COVID patients describe.
Mark
So the inflammation we already knew about is actually destroying these dopamine neurons?
Mimi
That's what the evidence suggests. The earlier study found inflammation in dopamine-rich regions. This new imaging shows the neurons themselves are injured. It's the missing link between what's happening in the tissue and what patients actually feel.
Mark
If existing dopamine drugs could help, why haven't they been tried yet?
Mimi
Because nobody had a reason to try them. Without knowing dopamine was damaged, there was no biological rationale. Now there is. That changes what doctors might consider.
Mark
Does this mean long COVID is finally understood?
Mimi
It's a major piece. But dopamine damage doesn't explain everything—there's likely inflammation, vascular issues, other systems involved. This identifies one clear target, not the whole picture.
Mark
What happens next?
Mimi
Clinical trials testing dopamine-enhancing drugs in long COVID patients. If they work, it validates the mechanism and gives millions of people an actual treatment option.
The Pulse
- Nine million Americans and roughly five percent of the global population remain trapped in a chronic condition that medicine has struggled to explain, let alone treat.
- PET brain scans have now captured something concrete: long COVID patients show measurable loss of dopamine nerve terminals across multiple regions of the striatum, the brain's hub for motivation, movement, and memory.
- The damage is not diffuse — lower dopamine markers in specific brain regions correspond with specific symptoms, transforming long COVID from a vague post-viral malaise into a condition with identifiable neurological roots.
- Prior research from the same team had already flagged elevated brain inflammation in long COVID; this new imaging closes the loop, showing that inflammation is actively injuring dopamine-producing neurons.
- Approved dopamine-enhancing drugs used in other neurological disorders now have a plausible biological target in long COVID patients, shifting the therapeutic conversation from speculation to repurposing.
For the millions living in the shadow of long COVID, the fog of exhaustion and lost motivation has long resisted explanation — and with it, the credibility that suffering often requires to be taken seriously. Now, PET imaging has revealed measurable damage to the brain's dopamine system in long COVID patients, with specific injuries mapping precisely onto specific symptoms: lost motivation, slowed movement, impaired memory. The discovery not only illuminates a biological mechanism behind one of the pandemic's most enduring legacies, but points toward existing medications that may, at last, offer relief.
For years, people living with long COVID have described an exhaustion that sleep cannot fix — a deep depletion of motivation and mental clarity that persists month after month. Researchers at the Centre for Addiction and Mental Health in Canada have now found something in the brain to match that experience: measurable damage to the dopamine system itself.
Using PET imaging, scientists scanned the brains of long COVID patients and compared them to healthy volunteers. Across multiple regions of the striatum — the brain's central hub for motivation, movement, learning, and memory — long COVID patients showed significantly lower levels of dopamine nerve terminals, the physical structures through which dopamine-releasing neurons communicate. The damage was not random. Lower dopamine markers in the ventral striatum correlated with loss of motivation; reductions in the dorsal putamen matched slower movement; lower levels in the caudate corresponded to memory problems. The brain scans were, in effect, reading the symptom list.
Long COVID affects approximately nine million adults in the United States and around five percent of the global population, defined by symptoms persisting at least three months after SARS-CoV-2 infection. Despite its scale, no evidence-based treatments exist — largely because the underlying biology remained opaque. This study builds on earlier work by the same team showing elevated inflammation in dopamine-rich brain regions, and now provides direct imaging evidence that this inflammation is injuring dopamine neurons, creating a biological chain that explains much of what patients experience.
The therapeutic implications are real and near-term. Several medications already approved for other neurological conditions work by increasing dopamine availability or enhancing dopamine signaling — drugs with established safety profiles that could be repurposed for long COVID. Beyond treatment, the imaging offers something patients have long been denied: objective, visible, measurable proof that what they are experiencing is real.
For years, people living with long COVID have described a particular kind of exhaustion—not the tiredness that sleep fixes, but a deeper depletion of motivation and mental clarity that persists month after month. Now, researchers have found something concrete in the brain to match that experience: measurable damage to the dopamine system itself.
A study published in eBioMedicine by scientists at the Centre for Addiction and Mental Health in Canada used PET imaging to scan the brains of long COVID patients and compare them to healthy volunteers. What they found was striking. Across multiple regions of the striatum—the brain's central hub for motivation, movement, learning, and memory—people with long COVID showed significantly lower levels of dopamine nerve terminals. These terminals are the physical structures through which dopamine-releasing neurons communicate. Their loss represents direct injury to the dopamine system.
The damage was not random. When researchers mapped the imaging results against patients' actual symptoms, the pattern became clear: lower dopamine markers in the ventral striatum correlated with loss of motivation; reductions in the dorsal putamen matched slower movement; and lower levels in the caudate corresponded to memory problems. It was as if the brain scans were reading the symptom list. This specificity matters. It suggests that long COVID is not simply a vague post-viral malaise but a condition with measurable biological roots in a particular neurological system.
Long COVID affects approximately nine million adults in the United States and roughly five percent of the global population. It is defined by symptoms persisting at least three months after initial SARS-CoV-2 infection—fatigue, brain fog, memory impairment, mood changes—and it has become one of the most common chronic conditions to emerge from the pandemic. Yet despite its scale, no evidence-based treatments exist, largely because doctors and researchers have not understood what was actually happening inside patients' brains.
This study builds on earlier work by the same group showing elevated inflammation in the brains of long COVID patients, particularly in regions rich in dopamine-producing neurons. Inflammation damages dopamine neurons in other neurological disorders; the new imaging provides direct evidence that this same inflammatory process is injuring dopamine neurons in long COVID. The connection between inflammation and dopamine loss, and between dopamine loss and specific symptoms, creates a biological chain that explains much of what patients experience.
The therapeutic implications are significant. Several medications already approved for other neurological conditions work by increasing dopamine availability or enhancing dopamine signaling. Dopamine precursors and drugs that inhibit dopamine metabolism could potentially be repurposed to treat long COVID's persistent cognitive and neurological symptoms. This is not speculative—these are existing drugs with known safety profiles, now with a plausible biological target in a new population.
For the millions of people who have lived with long COVID while doctors struggled to validate their symptoms, the imaging offers something else: objective evidence. The dopamine system damage is visible. It is measurable. It is real. That validation matters as much as the therapeutic pathway it opens.
Notable Quotes
Dopamine dysfunction plays a central role in long COVID, and existing dopamine-enhancing medications approved for other neurological disorders could represent a promising strategy for treatment— Research group at Centre for Addiction and Mental Health
Want the full story?
Read the original at Inside Precision Medicine ↗
Health & Medicine